GLPwatch
Papers (10401)
Page 63 of 174, ranked by citation count.
- Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
- Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.
- Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide.
- Insufficient sleep predicts poor weight loss maintenance after 1 year.
- Liraglutide therapy in Prader-Willi syndrome.
- Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.
- Synthesis and biological evaluation of an <sup>111</sup>In-labeled exendin-4 derivative as a single-photon emission computed tomography probe for imaging pancreatic β-cells.
- Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials.
- Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study.
- Managing Adverse Effects of Incretin-Based Medications for Obesity.
- A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes.
- Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus.
- Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.
- A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes.
- Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists.
- Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart.
- Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis.
- Indirect effects of glucagon-like peptide-1 receptor agonist exendin-4 on the peripheral circadian clocks in mice.
- The effect of glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms.
- Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy.
- Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.
- GLP-1 receptor agonists: A review of glycemic benefits and beyond.
- Effects of antidiabetic drugs on psoriasis: A meta-analysis.
- GLP-1 receptor agonist increases the expression of CTRP3, a novel adipokine, in 3T3-L1 adipocytes through PKA signal pathway.
- Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.
- Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis.
- Anti-obesity drugs' side effects: what we know so far.
- The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date.
- New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies.
- High dosage of Exendin-4 increased early insulin secretion in differentiated beta cells from mouse embryonic stem cells.
- Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort.
- Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications.
- EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.
- Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting.
- Efficacy of Intragastric Balloon versus Liraglutide as Bridge to Surgery in Super-Obese Patients.
- Glycemic variability in newly diagnosed diabetic cats treated with the glucagon-like peptide-1 analogue exenatide extended release.
- The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study.
- Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy.
- Newer antidiabetic drugs and calorie restriction mimicry.
- Combined therapy of mesenchymal stem cells with a GLP-1 receptor agonist, liraglutide, on an inflammatory-mediated diabetic non-human primate model.
- Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies.
- Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population.
- The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial.
- Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.
- An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists.
- Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon.
- GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner.
- Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system.
- The contribution of serotonin 5-HT2C and melanocortin-4 receptors to the satiety signaling of glucagon-like peptide 1 and liraglutide, a glucagon-like peptide 1 receptor agonist, in mice.
- Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers.
- Semaglutide treatment of hypothalamic obesity - a real-life data study.
- Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes.
- Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.
- Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study.
- Stability of exenatide in poly(D,L-lactide-co-glycolide) solutions: a simplified investigation on the peptide degradation by the polymer.
- Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges.
- Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.
- Enhanced protection against renal ischemia-reperfusion injury with combined melatonin and exendin-4 in a rodent model.
- Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review.